Looks like you’re on the UK site. Choose another location to see content specific to your location
Zoetis Unveils AI-Powered Haematology Breakthrough at London Vet Show
Zoetis, a global leader in animal health solutions, is set to unveil its AI-powered haematology analyzer, Vetscan OptiCell, during the London Vet Show. This device offers an innovative approach to blood analysis, providing significant time, cost, and space savings while promising enhanced outcomes for veterinary clinics. Showcased on Stand N50 at London Excel on November 14th and 15th, the Vetscan OptiCell represents a pivotal advancement in veterinary diagnostics.
Amid a rapidly evolving veterinary healthcare landscape, Zoetis’ introduction of the new device is a notable milestone. Leveraging AI technology for cell classification, this analyser ensures lab-quality CBC results directly at the point-of-care, streamlining clinical workflows.
Global Chief Medical Officer at Zoetis highlights the device’s capability to utilize AI image recognition for blood cell characterization, moving beyond traditional size-based methods. This pioneering technology not only boosts diagnostic accuracy but also optimizes operational efficiency within veterinary practices.
By integrating advanced AI technology into its haematology analyser, Zoetis is spearheading a transformation in veterinary diagnostics. The Vetscan OptiCell’s compact design and resource-efficient capabilities promise to redefine the standard for point-of-care testing. With pre-orders available in the UK by year-end, veterinary clinics are encouraged to embrace this innovation that heralds a new era of precision and efficiency in animal healthcare.
For the latest updates and in-depth insights into the world of Animal Health, including breakthrough technology, industry trends, and regulatory news, contact Poppy Hodge today!
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard